Buprenorphine Misuse among Heroin and Amphetamine Users in Malmo, Sweden: Purpose of Misuse and Route of AdministrationHakansson A.a · Medvedeo A.a · Andersson M.b · Berglund M.a
aDepartment of Clinical Alcohol Research, Lund University, Lund, and bDepartment of Infectious Diseases, Malmo University Hospital, Malmo, Sweden
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Buprenorphine misuse by injecting drug users was assessed in a survey of 350 needle exchangers, either amphetamine (57%) or heroin users (42%). 89% of heroin users and 24% of amphetamine users reported using buprenorphine at some time during the previous year. Most users reported illicit acquisition. Among illicit users, 87% of heroin users reported intake for withdrawal treatment or self-detoxification, and 11% for euphoria. Euphoria seeking was more common among amphetamine users (62%, p < 0.001). Intravenous misuse was reported by 43% of illicit users, and snorting by 29%. Sole sublingual intake was more common among heroin users than among amphetamine users (46 vs. 20%, p < 0.05), and less common among patients reporting euphoria seeking (20 vs. 46%, p < 0.05).
© 2007 S. Karger AG, Basel
Hakansson A, Medvedeo A, Berglund M: Prolonged retention with buprenorphine in in-patient opiate detoxification in Malmo, Sweden. Annual General Meeting of the Swedish Society of Medicine, Stockholm, 2005.
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction): The state of the drugs problem in Europe. Annual Report 2002. Luxembourg, EMCDDA, 2002.
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction): The state of the drugs problem in Europe. Annual Report 2005. Luxembourg, EMCDDA, 2005.
- Kraus L, Augustin R, Frischer M, Kümmler P, Uhl A, Wiessing L: Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. Addiction 2003;98:471–485.
Olsson B, Wahren CA, Byqvist S: The Extent of Heavy Drug Abuse in Sweden 1998. Stockholm, CAN, 2001.
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction): The state of the drugs problem in Europe. Annual Report 2004. Luxembourg, EMCDDA, 2004.
Heilig M: High or low threshold – that is not the question. Experiences from Sweden; in Waal H, Haga E (eds): Maintenance Treatment of Heroin Addiction – Evidence at the Crossroads. Oslo, Cappelen Akademisk Forlag, 2003, vol 1, pp 55–56.
FASS: Pharmaceutical Specialties in Sweden. Stockholm, 2004.
- Quigley AJ, Bredemeyer DE, Seow SS: A case of buprenorphine abuse. Med J Aust 1984;140:425–426.
Anonymous: Drug injectors in Glasgow: a community at risk? A report from a multidisciplinary group. The Possilpark Group. Health Bull (Edinb) 1993;51:418–429.
- Strang J: Abuse of buprenorphine. Lancet 1985;2(8457):725.
- Robinson GM, Dukes PD, Robinson BJ, Cooke RR, Mahoney GN: The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 1993;33:81–86.
- San L, Tremoleda J, Olle JM, Porta Serra M, de la Torre R: Prevalence of buprenorphine use by heroin addicts undergoing treatment. Med Clin (Barc) 1989;93:645–648.
Escots S, Fahet G: Usages non substitutifs de la buprénorphine haut dosage. Investigation menée en France en 2002–2003. Paris, TREND, OFDT (Observatoire francais des drogues et des toxicomanies), 2004.
- Blanchon T, Boissonnas A, Varescon I, Vidal-Trecan G: Homelessness and high-dosage buprenorphine misuse. Subst Use Misuse 2003;38:429–442.
- Varescon I, Vidal-Trecan G, Nabet N, Boissonnas A: Buprenorphine abuse: high dose intravenous administration of buprenorphine. Encephale 2002;28:397–402.
- Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti J-P: Injecting misuse of buprenorphine among French drug users. Addiction 2001;96:267–272.
- Jenkinson R, Clark N, Fry C, Dobbin M: Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005;100:197–205.
- Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A: Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003;69:175–181.
- Guichard A, Lert F, Calderon C, Gaigi H, Maguet O, Soletti J, Brodeur J-M, Richard L, Benigeri M, Zunzunegui M-V: Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction 2003;98:1585–1597.
- Barrau K, Thirion X, Micallef J, Chuniaud-Louche C, Bellemin B, San Marco JL: Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 2001;96:1433–1441.
Phan O, Sanchez M, Bouthillon-Heitzmann P: Absence de corrélation entre troubles psychiques et injection de buprénorphine haut dosage. Presse Méd 2005;34:711–718.
- Strang J: Abuse of buprenorphine (Temgesic) by snorting. BMJ 1991;302:969.
- Thiblin I, Eksborg S, Petersson A, Fugelstad A, Rajs J: Fatal intoxication as a consequence of intranasal administration (snorting) or pulmonary inhalation (smoking) of heroin. Forens Sci Int 2004;139:241–247.
- Eriksen J, Jensen NH, Kamp-Jensen M, Bjarno H, Friis P, Brewster D: The systemic availability of buprenorphine administered by nasal spray. J Pharm Pharmacol 1989;41:803–805.
- Leri F, Bruneau J, Stewart J: Understanding polydrug use: review of heroin and cocaine co-use. Addiction 2003;98:7–22.
- Walsh SL, Eissenberg T: The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003;70:S13–S27.
- Schottenfeld RS, Pakes J, O’Connor P, Chawarski M, Oliveto A, Kosten TR: Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry 2000;47:1072–1079.
- Chawarski MC, Schottenfeld RS, O’Connor PG, Pakes J: Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend 1999;55:157–163.
- Marsch LA, Bickel WK, Badger GJ, Jacobs EA: Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend 2005;77:195–204.
- Sigmon SC, Moody DE, Nuwayser ES, Bigelow GE: An injection depot formulation of buprenorphine: extended biodelivery and effects. Addiction 2006;101:420–432.
- Stoller KB, Bigelow GE, Walsh SL, Strain EC: Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 2001;154:230–242.
- Fudala PJ, Yu E, Macfadden W, Boardman C, Nora Chiang C: Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998;50:1–8.
- Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP: Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized opiate-dependent volunteers. Psychopharmacology 1999;141:37–46.
- Weinhold LL, Preston KL, Farre M, Liebson IA, Bigelow GE: Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend 1992;30:263–274.
- Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J: Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000;61:85–94.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.